prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.
3. The use as claimed in claim 1 or 2, wherein the blood plasma
fulvestrant concentration attained is at least 2.5 ngml-1 for at
least 2 weeks.
4. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the pharmaceutical
formulation comprises fulvestrant in solution, 30% or less
weight of a pharmaceutically-acceptable alcohol per volume